Hospital
Southeast Volusia Healthcare Corporation
Southeast Volusia Healthcare Corporation was paid $4.11M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoSOUTHEAST VOLUSIA HEALTHCARE CORPORATION
NEW SMYRNA BEACH, FL 32168
NEW SMYRNA BEACH, FL 32168
33aNPI1871977942assigned 07/17/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.11M
24GClaims115,016
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#90 of 163
Median peer was paid$4.77M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,583 | $91K | |
| 2019 | 21,627 | $641K | |
| 2020 | 18,135 | $567K | |
| 2021 | 24,803 | $852K | |
| 2022 | 26,741 | $965K | |
| 2023 | 12,217 | $710K | |
| 2024incomplete | 4,910 | $279K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 11,814 | 10,838 | $1.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 7,713 | 6,713 | $727K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 3,263 | 2,820 | $349K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.4% | 1,819 | 1,607 | $220K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.5% | 1,699 | 867 | $183K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 2,943 | 2,478 | $176K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 2,088 | 1,941 | $166K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 959 | 863 | $154K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.7% | 664 | 599 | $111K |
| 80053 | Comprehensive metabolic panel | 2.5% | 9,376 | 7,665 | $103K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 1,711 | 1,378 | $103K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 2,264 | 1,673 | $84K |
89 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 427 | $71K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 2,227 | $63K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 506 | $49K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,019 | $46K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 3,677 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 1,005 | $42K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,696 | $29K |
| 84484 | <1% | 2,655 | $28K | |
| 81001 | <1% | 2,881 | $23K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 504 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,383 | $17K |
| 81003 | <1% | 2,050 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 509 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,996 | $16K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,204 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 346 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 272 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,915 | $12K |
| 82947 | <1% | 1,140 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,135 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 353 | $11K |
| 81025 | <1% | 1,338 | $9K | |
| 80061 | Lipid panel | <1% | 872 | $9K |
| 73630 | <1% | 146 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 477 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 86 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 123 | $8K |
| 96376 | <1% | 166 | $7K | |
| 01999 | <1% | 274 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,457 | $5K |
| 83735 | <1% | 1,723 | $5K | |
| 85610 | <1% | 2,635 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 199 | $4K |
| 85730 | <1% | 2,026 | $3K | |
| 73130 | <1% | 26 | $3K | |
| 83605 | <1% | 1,008 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 66 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 435 | $3K |
| 87070 | <1% | 87 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 591 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,939 | $2K |
| 84702 | <1% | 154 | $2K | |
| 83880 | <1% | 292 | $2K | |
| 73110 | <1% | 27 | $1K | |
| 87040 | <1% | 1,076 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 79 | $1K |
| 83690 | <1% | 1,943 | $1K | |
| 82077 | <1% | 16 | $884.59 | |
| 73610 | <1% | 32 | $737.79 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 54 | $669.54 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 26 | $661.82 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 420 | $632.33 |
| 84703 | <1% | 740 | $543.86 | |
| 73562 | <1% | 13 | $522.58 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 40 | $460.65 |
| 0225U | <1% | 14 | $436.64 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 19 | $377.49 |
| 74018 | <1% | 12 | $309.06 | |
| 85379 | <1% | 180 | $281.87 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,471 | $258.78 |
| 80050 | General health panel | <1% | 13 | $255.81 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,252 | $168.54 |
| 87077 | <1% | 201 | $81.58 | |
| 82565 | <1% | 62 | $73.20 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 302 | $71.16 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 226 | $50.99 |
| 85027 | <1% | 276 | $46.13 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 77 | $37.88 |
| 86140 | <1% | 33 | $25.12 | |
| 84439 | <1% | 76 | $20.45 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 251 | $14.61 |
| 85007 | <1% | 29 | $3.51 | |
| 84520 | <1% | 18 | $1.68 | |
| J2704 | Injection, propofol, 10 mg | 0% | 35 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 84 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 32 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 13 | $0.00 |
| 84132 | 0% | 16 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 14 | $0.00 |
| 86901 | 0% | 58 | $0.00 | |
| 86850 | 0% | 13 | $0.00 | |
| 85652 | 0% | 16 | $0.00 | |
| 87186 | 0% | 260 | $0.00 | |
| 80305 | 0% | 25 | $0.00 | |
| 86900 | 0% | 59 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 36 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 14 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZILL, KENNETH (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Southwest Volusia Healthcare Corporation | Orange City, FL | $17.10M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.